Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis
Neurology and Therapy · 2026-08 · 15 (4) · 1573-1591
DOI: 10.1007/s40120-026-00939-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 27.04.2026. Verfasst von Mohita Kumar und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCB, Atlanta, GA, USA. Mohita.Kumar@ucb.com. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB.
Abstract (Originalsprache)
INTRODUCTION: Rozanolixizumab is indicated for the treatment of adults with generalized myasthenia gravis (MG). This retrospective, non-interventional cohort study evaluated adults with MG initiating rozanolixizumab in the USA. METHODS: Patients were selected from de-identified claims data from the Komodo Healthcare Map® (July 2023-March 2025). Enrolled patients were aged ≥ 18 years with MG diagnosis, ≥ 1 rozanolixizumab medical/pharmacy claim, and continuous enrollment/plan coverage for 12 months (baseline period) before first rozanolixizumab treatment initiation (index date). The follow-up period was from 1 day post-index to last enrollment date. Treatment patterns and healthcare resource utilization (HCRU) were assessed during baseline and follow-up. A second study (July 2023-June 2024) assessed patients for 12 months post-index who had ≥ 1 efgartigimod claim ≤ 12 months prior to index. RESULTS: The main study included 719 patients. Patients with ≥ 365 days since rozanolixizumab initiation (n = 287) started a mean (standard deviation) 2.9 (1.8) treatment cycles in Year 1. Total MG-related HCRU incidence rates per 100 person-years were 88.0 during baseline and 82.9 during follow-up, and 86.2 versus 80.8 for outpatient, 25.6 versus 17.3 for inpatient, and 24.9 versus 14.0 for emergency room visits. Approximately half (53.7%, 386/719) of patients used corticosteroids at baseline and had ≥ 3 months' follow-up. 29.0% (n = 112) tapered their dose by ≥ 5 mg, and a further 29.3% (n = 113) discontinued corticosteroids during follow-up. In patients who had ≥ 1 claim for efgartigimod before initiating rozanolixizumab (n = 26), 19.2% tapered corticosteroids by ≥ 5 mg during follow-up, and 7.7% discontinued completely. CONCLUSION: This real-world study of patients receiving rozanolixizumab in the USA showed reductions in corticosteroid use and HCRU following rozanolixizumab initiation, including in those who switched from efgartigimod. The mean number of rozanolixizumab cycles (2.9) was lower than the mean 4.1 cycles in Phase 3 studies (patients with ≥ 1 year of follow-up), demonstrating that treatment patterns in clinical practice can be individually adjusted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UCB, Atlanta, GA, USA. Mohita.Kumar@ucb.com.
- UCB, San Francisco, CA, USA.
- Alira Health, Basel, Switzerland.
- Alira Health, Framingham, MA, USA.
- UCB, Monheim, Germany.
- UCB, Madrid, Spain.
Förderung
- UCB
Zitieren
APA
Kumar, M., Harrold, A., Park, M., Nair, A., Bardenheuer, K., Tarancón, T., Ting, A., & Pata, D. (2026). Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis. Neurology and Therapy, 15(4), 1573-1591. https://doi.org/10.1007/s40120-026-00939-7
Vancouver
Kumar M, Harrold A, Park M, Nair A, Bardenheuer K, Tarancón T, et al. Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis. Neurology and Therapy. 2026;15(4):1573-1591. doi:10.1007/s40120-026-00939-7
BibTeX
@article{Kumar2026,
author = {Kumar, Mohita and Harrold, Alexandria and Park, Minjee and Nair, Aaksa and Bardenheuer, Kristina and Tarancón, Thaïs and Ting, Angela and Pata, Diogo},
title = {Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis},
journal = {Neurology and Therapy},
year = {2026},
volume = {15},
number = {4},
pages = {1573--1591},
doi = {10.1007/s40120-026-00939-7}
}
EUVIMED